# Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer

> **NCT00636883** · PHASE2 · TERMINATED · sponsor: **National Guard Health Affairs** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00636883
- **Lead sponsor:** National Guard Health Affairs
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** slow accrual rate
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636883, "Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00636883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*